PET and Planar Imaging of Tumor Hypoxia With Labeled Metronidazole

Academic Radiology

Volumn 13, Issue 5, 2006, Pages 598-609

  Ito, Megumi ^a   Yang, David J ^a   Mawlawi, Osama ^a   Mendez, Richard ^a   Oh, Chang Sok ^a   Azhdarinia, Ali ^a   Greenwell, Allison C ^a   Yu, Dong Fang ^a   Kim, E Edmund ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

68Ga ethylenedicysteine metronidazole; 99mTc ethylenedicysteine metronidazole; hypoxia; imaging

Indexed keywords

CHELATING AGENT; ETHYLENEDICYSTEINE; GALLIUM 68; METRONIDAZOLE; TECHNETIUM 99M; TIN CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CELL LABELING; CONTROLLED STUDY; EVALUATION; FEMALE; HUMAN; HUMAN CELL; HYPOXIC CELL; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MEDICAL ASSESSMENT; NONHUMAN; OXYGEN AFFINITY; OXYGEN TENSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; TUMOR BLOOD FLOW; TUMOR CELL;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; FEASIBILITY STUDIES; FEMALE; ISOTOPE LABELING; LUNG NEOPLASMS; METABOLIC CLEARANCE RATE; METRONIDAZOLE; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, INBRED F344; TISSUE DISTRIBUTION;

EID: 33646039330     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2006.01.007     Document Type: Article

References (37)

1. Brown J.M. The hypoxic cell. a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59 (1999) 5863-5870
2. Rockwell S. Oxygen delivery. implications for the biology and therapy of solid tumors. Oncol Res 9 (1997) 383-390
3. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1196; 56:4509-4515.
4. Brizel D.M., Scully S.P., Harrelson J.M., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56 (1996) 941-943
5. Brizel D.M., Sibley G.S., Prosnitz L.R., et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38 (1997) 285-289
6. Liang B.C. Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurooncol 29 (1996) 149-155
7. Giaccia A.J. Hypoxic stress proteins. survival of the fittest. Semin Radiat Oncol 6 (1996) 46-58
8. Graeber T.G., Osmanian C., Jacks T., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379 (1996) 88-91
9. Dai S., Huang M.L., Hsu C.Y., et al. Inhibition of hypoxia inducible factor 1alpha causes oxygen-independent cytotoxicity and induces p53 independent apoptosis in glioblastoma cells. Int J Radiat Oncol Biol Phys 55 (2003) 1027-1036
10. Chu T., Li R., Hu S., et al. Preparation and biodistribution of technetium-99m-labeled 1-(2-nitroimidazole-1-yl)-propanhydroxyiminoamide (N2IPA) as a tumor hypoxia marker. Nucl Med Biol 3 (2004) 199-203
11. Seddon B.M., Maxwell R.J., Honess D.J., et al. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clin Cancer Res 8 (2002) 2323-2335
12. Bentzen L., Keiding S., Nordsmark M., et al. Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol 67 (2003) 339-344
13. Gronroos T., Bentzen L., Marjamaki P., et al. Comparison of the biodistribution of two hypoxia markers [18F] FETNIM and [18F] FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 31 (2004) 513-520
14. Efange S.M., Kung H.F., Billings J., et al. Technetium-99m bis (aminoethanethiol) complexes with amine sidechains-potential brain perfusion imaging agents for SPECT. J Nucl Med 28 (1987) 1012-1019
15. Anderson C.J., John C.S., Li Y.J., et al. N,N′-ethylene-di-L-cysteine (EC) complexes of Ga(III) and In(III). molecular modeling, thermodynamic stability and in vivo studies. Nucl Med Biol 22 (1995) 165-173
16. Zareneyrizi F., Yang D.J., Oh C.S., et al. Synthesis of 99mTc-ethylenedicysteine-colchicine for evaluation of antiangiogenic effect. Anticancer Drugs 10 (1999) 685-692
17. Yang D.J., Azhdarinia A., Wu P., et al. In vivo and in vitro measurement of apoptosis in breast cancer cells using 99mTc-EC-annexin V. Cancer Biother Radiopharm 16 (2001) 73-83
18. Yang D.J., Kim K.D., Schechter N.R., et al. Assessment of antiangiogenic effect using 99mTc-EC-endostatin. Cancer Biother Radiopharm 17 (2002) 233-245
19. Schechter N.R., Yang D.J., Azhdarinia A., et al. Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody. Anticancer Drugs 14 (2003) 49-56
20. Yang D.J., Kim C.G., Schechter N.R., et al. Imaging with 99mTc ECDG targeted at the multifunctional glucose transport system. feasibility study with rodents. Radiology 226 (2003) 465-473
21. 99mTc-ethylenedicysteine-folate: a new tumor imaging agent. Synthesis, labeling and evaluation in animals. Cancer Biother Radiopharm 13 (1998) 427-435
22. Song H.C., Bom H.S., Cho K.H., et al. Prognostication of recovery in patients with acute ischemic stroke using brain SPECT with 99mTc-metronidazole. Stroke 34 (2003) 982-986
23. 99mTc-labeled Celebrex. Anti-Cancer Drugs 15 (2004) 255-263
24. Zheng Y.Y., Saluja S., Yap G.P., et al. Gallium and indium complexes of bis(amino thiol) (N(2)S(2)) ligands. Inorg Chem 35 (1996) 6656-6666
25. Sun Y., Anderson C.J., Pajeau T.S., et al. Indium (III) and gallium (III) complexes of bis(aminoethanethiol) ligands with different densities. stabilities, molecular modeling, and in vivo behavior. J Med Chem 39 (1996) 458-470
26. Teicher B.A., and Sotomayor E.A. Chemical radiation sensitizers and protectors. In: Foye W.P. (Ed). Cancer chemotherapeutic agents (1995), American Chemical Society, Washington, DC 501-527
27. Hay M.P., Wilson W.R., Moselen J.W., et al. Hypoxia-selective antitumor agents. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitizers. J Med Chem 37 (1994) 381-391
28. Ratner S., and Clarke H. The action of formaldehyde upon cysteine. J Am Chem Soc 59 (1937) 200-206
29. Blondeau P., Berse C., and Gravel D. Dimerization of an intermediate during the sodium in liquid ammonia reduction of L-thiazolidine-4-carboxylic acid. Can J Chem 45 (1967) 49-52
30. Yang D.J., Ilgan S., Higuchi T., et al. Noninvasive assessment of tumor hypoxia with 99mTc labeled metronidazole. Pharm Res 16 (1999) 743-750
31. Stabin M. MIRDOSE. the personal computer software for use in internal dose assessment in nuclear medicine. J Nucl Med 37 (1996) 538-546
32. Knoess C., Siegel S., Smith A., et al. Performance evaluation of the microPET R4 PET scanner for rodents. Eur J Nucl Med Mol Imaging 30 (2003) 737-747
33. 18F] fluoromisonidazole and PET. J Nucl Med 33 (1992) 2202-2208
34. Yeh S.H., Liu R.S., Hu H.H., et al. Ischemic penumbra in acute stroke. demonstration by PET with fluorine-18 fluoromisonidazole. J Nucl Med 35 (1994) 205
35. Yeh S.H., Liu R.S., Wu L.C., et al. Fluorine-18 fluoromisonidazole tumor to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 23 (1996) 1378-1383
36. 18F] fluoromisonidazole. J Nucl Med 35 (1994) 113
37. Verbruggen A.M., Nosco D.L., Van Nerom C.G., et al. Tc-99m-L,L-ethylenedicysteine: a renal imaging agent. I. Labelling and evaluation in animals. J Nucl Med 33 (1992) 551-557